BMS-986148

DRUG2 trials

Sponsors

Bristol-Myers Squibb

Conditions

Advanced Cancer

Phase 1

A Study of BMS-986148 in Patients With Select Advanced Solid Tumors

TerminatedNCT02341625

Bristol-Myers SquibbAdvanced Cancer

Start: 2015-06-19End: 2020-05-07Updated: 2022-08-18

Phase 1 Study of Mesothelin-ADC

CompletedNCT02884726

Bristol-Myers SquibbAdvanced Cancer

Start: 2016-10-14End: 2017-09-06Updated: 2020-03-19

Related Papers

Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors

Clinical Cancer Research2021-10-0654 citations

Abstract B057: BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors

Molecular Cancer Therapeutics2019-12-0117 citations